Drug development for anticancer therapy: Discovery of New Inhibitors for Lin28

Prostate cancer is the most prevalent malignancy among Canadian men. While treatments exist, many tumors are resistant, highlighting the urgent need to develop more effective therapies. This project aims to develop new drugs for prostate cancer by inhibiting the Lin28 protein, which increases cancer cells’ growth and resistance to treatments. This will be achieved by combining virtual chemical analysis with laboratory research. This project intends to forge new international bonds and exchange of ideas between the Peruvian and Canadian institutions. The search for new Lin28 inhibitors is fundamental, as it offers opportunities to overcome the limitations of efficacy, specificity, and safety of the current few explored inhibitors. The successful development and clinical application of these inhibitors could improve treatment outcomes for prostate cancer patients, promising more tailored and specific treatment strategies, addressing drug resistance, and improving the safety profile of cancer therapies by reducing adverse effects on healthy cells.

Faculty Supervisor:

Xuesen Dong

Student:

Partner:

Universidad César Vallejo

Discipline:

Life Sciences

Sector:

Education

University:

The University of British Columbia

Program: